349 related articles for article (PubMed ID: 19049556)
1. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy.
Cooper JM; Korlipara LV; Hart PE; Bradley JL; Schapira AH
Eur J Neurol; 2008 Dec; 15(12):1371-9. PubMed ID: 19049556
[TBL] [Abstract][Full Text] [Related]
2. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.
Hart PE; Lodi R; Rajagopalan B; Bradley JL; Crilley JG; Turner C; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
Arch Neurol; 2005 Apr; 62(4):621-6. PubMed ID: 15824263
[TBL] [Abstract][Full Text] [Related]
3. Friedreich's Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy.
Cooper JM; Schapira AH
Biofactors; 2003; 18(1-4):163-71. PubMed ID: 14695932
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial dysfunction in Friedreich's ataxia: from pathogenesis to treatment perspectives.
Lodi R; Rajagopalan B; Bradley JL; Taylor DJ; Crilley JG; Hart PE; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
Free Radic Res; 2002 Apr; 36(4):461-6. PubMed ID: 12069111
[TBL] [Abstract][Full Text] [Related]
5. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study.
Meier T; Perlman SL; Rummey C; Coppard NJ; Lynch DR
J Neurol; 2012 Feb; 259(2):284-91. PubMed ID: 21779958
[TBL] [Abstract][Full Text] [Related]
6. Human neuronal coenzyme Q10 deficiency results in global loss of mitochondrial respiratory chain activity, increased mitochondrial oxidative stress and reversal of ATP synthase activity: implications for pathogenesis and treatment.
Duberley KE; Abramov AY; Chalasani A; Heales SJ; Rahman S; Hargreaves IP
J Inherit Metab Dis; 2013 Jan; 36(1):63-73. PubMed ID: 22767283
[TBL] [Abstract][Full Text] [Related]
7. Cosupplementation with vitamin E and coenzyme Q10 reduces circulating markers of inflammation in baboons.
Wang XL; Rainwater DL; Mahaney MC; Stocker R
Am J Clin Nutr; 2004 Sep; 80(3):649-55. PubMed ID: 15321805
[TBL] [Abstract][Full Text] [Related]
8. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial.
Di Prospero NA; Baker A; Jeffries N; Fischbeck KH
Lancet Neurol; 2007 Oct; 6(10):878-86. PubMed ID: 17826341
[TBL] [Abstract][Full Text] [Related]
9. Coenzyme Q biosynthesis in health and disease.
Acosta MJ; Vazquez Fonseca L; Desbats MA; Cerqua C; Zordan R; Trevisson E; Salviati L
Biochim Biophys Acta; 2016 Aug; 1857(8):1079-1085. PubMed ID: 27060254
[TBL] [Abstract][Full Text] [Related]
10. Neurophysiological evaluation in children with Friedreich's ataxia.
Sival DA; du Marchie Sarvaas GJ; Brouwer OF; Uges DR; Verschuuren-Bemelmans CC; Maurits NM; Brunt ER; van der Hoeven JH
Early Hum Dev; 2009 Oct; 85(10):647-51. PubMed ID: 19775837
[TBL] [Abstract][Full Text] [Related]
11. Idebenone in Friedreich's ataxia.
Tonon C; Lodi R
Expert Opin Pharmacother; 2008 Sep; 9(13):2327-37. PubMed ID: 18710357
[TBL] [Abstract][Full Text] [Related]
12. Coenzyme Q(10)-responsive ataxia: 2-year-treatment follow-up.
Pineda M; Montero R; Aracil A; O'Callaghan MM; Mas A; Espinos C; Martinez-Rubio D; Palau F; Navas P; Briones P; Artuch R
Mov Disord; 2010 Jul; 25(9):1262-8. PubMed ID: 20629161
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
Storch A; Jost WH; Vieregge P; Spiegel J; Greulich W; Durner J; Müller T; Kupsch A; Henningsen H; Oertel WH; Fuchs G; Kuhn W; Niklowitz P; Koch R; Herting B; Reichmann H;
Arch Neurol; 2007 Jul; 64(7):938-44. PubMed ID: 17502459
[TBL] [Abstract][Full Text] [Related]
14. Clinical aspects of coenzyme Q10: an update.
Littarru GP; Tiano L
Curr Opin Clin Nutr Metab Care; 2005 Nov; 8(6):641-6. PubMed ID: 16205466
[TBL] [Abstract][Full Text] [Related]
15. Friedreich's ataxia: coenzyme Q10 and vitamin E therapy.
Cooper JM; Schapira AH
Mitochondrion; 2007 Jun; 7 Suppl():S127-35. PubMed ID: 17485244
[TBL] [Abstract][Full Text] [Related]
16. Efficient attenuation of Friedreich's ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA.
Lee YK; Lau YM; Ng KM; Lai WH; Ho SL; Tse HF; Siu CW; Ho PW
Int J Cardiol; 2016 Jan; 203():964-71. PubMed ID: 26625322
[TBL] [Abstract][Full Text] [Related]
17. Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia - open-label trial.
Arpa J; Sanz-Gallego I; Rodríguez-de-Rivera FJ; Domínguez-Melcón FJ; Prefasi D; Oliva-Navarro J; Moreno-Yangüela M
Acta Neurol Scand; 2014 Jan; 129(1):32-40. PubMed ID: 23668357
[TBL] [Abstract][Full Text] [Related]
18. Triple therapy with darbepoetin alfa, idebenone, and riboflavin in Friedreich's ataxia: an open-label trial.
Arpa J; Sanz-Gallego I; Rodríguez-de-Rivera FJ; Domínguez-Melcón FJ; Prefasi D; Oliva-Navarro J; Moreno-Yangüela M; Pascual-Pascual SI
Cerebellum; 2013 Oct; 12(5):713-20. PubMed ID: 23625326
[TBL] [Abstract][Full Text] [Related]
19. Friedreich's ataxia: idebenone treatment in early stage patients.
Artuch R; Aracil A; Mas A; Colomé C; Rissech M; Monrós E; Pineda M
Neuropediatrics; 2002 Aug; 33(4):190-3. PubMed ID: 12368988
[TBL] [Abstract][Full Text] [Related]
20. Friedreich's ataxia: from disease mechanisms to therapeutic interventions.
Lodi R; Tonon C; Calabrese V; Schapira AH
Antioxid Redox Signal; 2006; 8(3-4):438-43. PubMed ID: 16677089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
